CYP2C9 and hepatocellular carcinoma: For clinical translation, three validation tiers are essential: First, analytical validation via qPCR/Nanostring in retrospective HCC tissue banks should assess technical reproducibility of top candidates (e.g., CYP2C9 for metabolic dysfunction, GADD45B for HBV-specific progression).